Acetylleucine Explained

Acetylleucine is a modified amino acid used in the treatment of vertigo[1] and cerebellar ataxia.

Acetylleucine is also being developed as a possible treatment for several neurological disorders by IntraBio Inc.[2] Clinical trials with acetylleucine for the treatment of three orphan, fatal, neurodegenerative disorders are underway: Niemann-Pick disease type C,[3] GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases),[4] and ataxia–telangiectasia.[5] In 2020, IntraBio announced the successful multinational clinical trial results of the Niemann-Pick type C clinical trial.[6] IntraBio is also investigating acetylleucine for the treatment of common inherited and acquired neurological diseases including Lewy body dementia,[7] amyotrophic lateral sclerosis, restless legs syndrome, multiple sclerosis, and migraine[8] Acetylleucine has received orphan drug designations from the U.S. Food & Drug Administration (FDA)[9] [10] [11] [12] and the European Commission.[13] [14] [15] [16]

See also

References

  1. Web site: N07CA04 (acetylleucine) . WHO Collaborating Centre for Drug Statistics Methodology . Norwegian Institute of Public Health . 19 Dec 2016 . 26 Mar 2017.
  2. Web site: IntraBio. en-GB. 2019-08-01. https://web.archive.org/web/20190801041947/http://intrabio.com/for-medical-professionals/. 2019-08-01. dead.
  3. Web site: N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) - Full Text View - ClinicalTrials.gov. clinicaltrials.gov. en. 2019-08-01.
  4. Web site: N-Acetyl-L-Leucine for GM2 Gangliosdisosis (Tay-Sachs and Sandhoff Disease) - Full Text View - ClinicalTrials.gov. clinicaltrials.gov. en. 2019-08-01.
  5. Web site: N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) - Full Text View - ClinicalTrials.gov. clinicaltrials.gov. en. 2019-08-01.
  6. Web site: IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C. intrabio.com. 19 October 2020 . 2021-08-01.
  7. A clinical trial to test amlodipine as a new treatment for vascular dementia. Passmore. Peter. 2014-04-15. 10.1186/isrctn31208535 . free .
  8. Strupp. Michael. Bayer. Otmar. Feil. Katharina. Straube. Andreas. 2019-02-01. Prophylactic treatment of migraine with and without aura with acetyl-dl-leucine: a case series. Journal of Neurology. en. 266. 2. 525–529. 10.1007/s00415-018-9155-6. 30547273. 56148131. 1432-1459.
  9. Web site: Search Orphan Drug Designations and Approvals. www.accessdata.fda.gov. 2019-08-03.
  10. Web site: Search Orphan Drug Designations and Approvals. www.accessdata.fda.gov. 2019-08-03.
  11. Web site: Search Orphan Drug Designations and Approvals. www.accessdata.fda.gov. 2019-08-03.
  12. Web site: Search Orphan Drug Designations and Approvals. www.accessdata.fda.gov. 2019-08-03.
  13. Web site: Public Health - European Commission. Union Register of medicinal products. en. 2019-08-03.
  14. Web site: Public Health - European Commission. Union Register of medicinal products. en. 2019-08-03.
  15. Web site: Public Health - European Commission. Union Register of medicinal products. en. 2019-08-03.
  16. Web site: Public Health - European Commission. Union Register of medicinal products. en. 2019-08-03.